Rchr
J-GLOBAL ID：201801017570857957
Update date: Aug. 02, 2024
Narumi Ryohei
ナルミ リョウヘイ | Narumi Ryohei
Affiliation and department：
Research field (1)：
Molecular biology
Research theme for competitive and other funds (2)：
- 2019 - 2021 co-expression analysis and kinase activity estimation using proteomic data of cancer cells toward drug efficacy prediction
- 2015 - 2017 Proteome analysis for low abundant ptoteins
Papers (30)：
-
Katsuhiko Matsumoto, Shoko Y. Harada, Shota Y. Yoshida, Ryohei Narumi, Tomoki T. Mitani, Saori Yada, Aya Sato, Eiichi Morii, Yoshihiro Shimizu, Hiroki R. Ueda. Genome-wide epitope identification with single-amino-acid resolution via high-throughput and unbiased peptide analysis. 2024
-
Yosui Nojima, Masahiko Aoki, Suyong Re, Hidekazu Hirano, Yuichi Abe, Ryohei Narumi, Satoshi Muraoka, Hirokazu Shoji, Kazufumi Honda, Takeshi Tomonaga, et al. Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines. Computational and Structural Biotechnology Journal. 2023
-
Daigo Gunji, Ryohei Narumi, Satoshi Muraoka, Junko Isoyama, Narumi Ikemoto, Mimiko Ishida, Takeshi Tomonaga, Yoshiharu Sakai, Kazutaka Obama, Jun Adachi. Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer. Molecular Omics. 2023
-
Keiko Kasahara, Ryohei Narumi, Satoshi Nagayama, Keiko Masuda, Tsuyoshi Esaki, Kazutaka Obama, Takeshi Tomonaga, Yoshiharu Sakai, Yoshihiro Shimizu, Jun Adachi. A large-scale targeted proteomics of plasma extracellular vesicles shows utility for prognosis prediction subtyping in colorectal cancer. Cancer Medicine. 2022
-
Eisuke Tomiyama, Kazutoshi Fujita, Kyosuke Matsuzaki, Ryohei Narumi, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Yoko Koh, Makoto Matsushita, Yujiro Hayashi, et al. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer. British journal of cancer. 2022
ｍore...
MISC (21)：
-
Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Ryohei Narumi, Jun Adachi, Ryotaro Sakamori, Naruyasu Kakita, Yukinori Yamada, Tatsuya Sakamoto, Machiko Kai, et al. SERUM Fibulin3 IS A NOVEL FIBROSIS MARKER IN NAFLD REVEALED BY PROTEOMIC ANALYSIS OF SERUM EXTRACELLULAR VESICLES. HEPATOLOGY. 2022. 76. S801-S801
-
冨山 栄輔, 藤田 和利, 松崎 恭介, 白水 崇, 鳴海 良平, 神宮司 健太郎, 加藤 大悟, 波多野 浩士, 河嶋 厚成, 氏家 剛, et al. 尿中および組織分泌細胞外小胞のプロテオミクス解析による新規膀胱癌バイオマーカーの探索. 日本分子腫瘍マーカー研究会誌. 2022. 37. 16-17
-
冨山 栄輔, 藤田 和利, 松崎 恭介, 白水 崇, 鳴海 良平, 神宮司 健太郎, 加藤 大悟, 波多野 浩士, 河嶋 厚成, 氏家 剛, et al. 尿中および組織分泌細胞外小胞のプロテオミクス解析による新規膀胱癌バイオマーカーの探索. 日本分子腫瘍マーカー研究会プログラム・講演抄録. 2021. 41回. 50-51
-
二見 悠, 武田 吉人, 木庭 太郎, 中山 真菜, 森 雅秀, 鳴海 良平, 足立 淳, 植田 幸嗣, 井上 義一, 熊ノ郷 淳. エクソソームの次世代プロテオミクスによるサルコイドーシスの新規バイオマーカー同定. 日本サルコイドーシス/肉芽腫性疾患学会雑誌. 2020. 40. サプリメント号. 61-61
-
石津谷 祐, 鳴海 良平, 洪 陽子, 王 聡, 神宮司 健太郎, 加藤 大悟, 河嶋 厚成, 氏家 剛, 永原 啓, 藤田 和利, et al. 去勢抵抗性前立腺癌患者の血清エクソソームの網羅的タンパク解析による新規治療標的の探索と同定. 日本泌尿器科学会総会. 2019. 107回. AOP-112
ｍore...
Awards (1)：
- 2017/07 - Japanese Proteomic Society Japanese Proteomics Society Young Investigator Award Targeted proteomics based absolute quantification using cell-free synthesized peptides
Return to Previous Page
